|
There was no reported device malfunction and the device was not returned for analysis.A review has been performed of the manufacturing certificate of conformance associated with this lot.There were no non-conformances or deviations which could be associated with this event.Based on the case information and related record review, a conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.The reported patient effect of restenosis leading to intervention is a known patient effect of peripheral stenting procedures.There is no indication of a product quality issue with respect to the design, manufacture or labelling of the device.If further information regarding this event becomes available, a follow-up report will be submitted.
|
|
The patient was enrolled in the mimics 3d usa post-market observational study.On (b)(6) 2021, the patient was implanted with one biomimics 3d (bm3d) 6.0 x 150 mm stent to treat a restenotic lesion in the left superficial femoral artery (sfa) distal third to proximal popliteal artery.A contralateral approach was used and the lesion was pre-dilated with percutaneous transluminal angioplasty (pta) and atherectomy.On (b)(6) 2022, a restenosis of the treated segment (target lesion) was identified and it was reported as possibly related to the device and not related to the procedure.It was target lesion-related.It required laser atherectomy of the sfa middle third to the posterior tibial proximal third on (b)(6) 2022.The intervention was a target lesion/vessel revascularisation (tlr/tvr).The outcome was reported as resolved/recovered.The device remains implanted.Veryan became aware of this event on (b)(6) 2024.
|